

Dr. rer. nat. Olaf Klingbeil

Postdoctoral Fellow

Cold Spring Harbor Laboratory

1 Bungtown Road, 11724 Cold Spring Harbor NY

Email: klingbe@cshl.edu

RESEARCH EXPERIENCE

2017-present **Postdoc** at Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, laboratory of Dr. Vakoc.



2014-2016 **Graduate Student** at Bayer Pharma AG, Therapeutic Research Group Oncology Berlin, Germany, laboratory of Dr. Lejeune and Dr. Haendler



2013-2014 **Master thesis** at Bayer Pharma AG, Therapeutic Research Group Oncology Berlin, Germany, laboratory of Dr. Lejeune



2012 **Intern** at Department of Experimental and Clinical Pharmacology and Toxicology at University of Lübeck, Germany, laboratory of Dr. Müller-Fielitz



2011 **Bachelor thesis** at the Department of Experimental and Clinical Pharmacology and Toxicology at University of Lübeck, Germany, laboratory of Dr. Joehren



EDUCATION

2016 **Dr. rer. nat.** in Molecular Biology, Humboldt University of Berlin, Germany

2013 **M.sc.** Molecular Life Science, University of Lübeck, Germany

2011 **B.sc.** in Molecular Life Science, University of Lübeck, Germany

FELLOWSHIPS AND AWARDS

2018-present DFG Research Fellowship

2011-2013 Life Science e.V. Fellowship

PUBLICATIONS

Lu B, **Klingbeil O**, Tarumoto Y, Somerville TDD, Huang YH, Wei Y, et al. A transcription factor addiction in leukemia imposed by the MLL promoter sequence. accepted manuscript. *Cancer Cell*. 2018

Huang YH, **Klingbeil O**, He XY, Wu XS, Arun G, Lu B, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. *Genes Dev*. 2018;32(13-14):915-28.

Tarumoto Y, Lu B, Somerville TDD, Huang YH, Milazzo JP, Wu XS, **Klingbeil O**, et al. LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. *Mol Cell*. 2018;69(6):1017-27 e6.

Gelato KA*, Schockel L*, **Klingbeil O***, Ruckert T, Lesche R, Toedling J, et al. Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition. *Oncogene*. 2018;37(4):512-21. *Equal contribution

Klingbeil O. Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer: Lebenswissenschaftliche Fakultät; 2016.

Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. *Cell Death Dis*. 2016;7(9):e2365.